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The occurrence of signs and symptoms of heart failure
(HF) with normal left ventricular ejection fraction and
predominant anomalies of left ventricular (LV) relaxa-
tion and stiffness (i.e. diastolic HF) is increasingly recog-
nized. Notably, in recent years survival rate of systolic
HF has improved, whereas the prognosis for diastolic
HF remains unchanged. This may be in part attributable
to the lack of additional benefits by treatments’ options
used as standard care of systolic HF.
PDE5 inhibition is an emerging therapy proposed for
HF treatment that enhances NO signaling by increasing
the cyclic guanosine monophosphate (cGMP) availabil-
ity. This pharmacological property seems especially
attractive for patients with left ventricular hypertrophy
and diastolic HF [1]. In experimental models of failing
hearts due to pressure overload and diastolic dysfunc-
tion, PDE5 inhibition has been shown to promote a
reverse left ventricular (LV) chamber remodeling by
modulating LV hypertrophy and fibrosis [2]. Preliminary
observations in humans confirm the ability of long-term
PDE5 inhibition administration by sildenafil to improve
cardiac geometry, LV mass and diastolic function [3].
Recent community based studies [4] have highlighted
that a considerable number of patients with diastolic HF
present with left-sided Group 2 pulmonary hypertension
suggesting a tight pathophysiological relationship
between LV hypertrophy, increasing LV filling pressures
and abnormalities of pulmonary vascular tone and per-
meability. Interestingly, development of pulmonary
hypertension strongly discriminates survival rate.
Although in these patients alterations of many signal-
ing pathways may be unique to the heart or pulmonary
vasculature, downregulation of the NO-cGMP pathway
seems to be a common finding in both locations.
Accordingly, in an effort to better understand the com-
bined role of this pathway in both the heart and the
lung vasculature, we recently performed a study aimed
at testing the hypothesis that diastolic HF patients at
higher risk for the unfavorable upstream effects of an
increased left atrial pressure would benefit of chronic
PDE5 inhibition with sildenafil. Specifically, we hypothe-
sized that sildenafil would modulate pulmonary vascular
tone and RV hemodynamic burden. A significant
improvement in pulmonary hemodynamics, right ventri-
cular contractility and chamber dimensions were
observed at 6 and 12 months of follow-up. These effects
were paralleled by an improvement in quality of life and
clinical status [5].
Although the available experimental and clinical data
seem promising, further large-scale morbidity and mor-
tality studies are necessary to provide a definitive appre-
ciation onto whether PDE5 inhibition may effectively
impact the natural history of HF due to diastolic origin.
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